Activin and Inhibin

ALDH1A3-IN-2 (Compound 15) is a potent inhibitor of ALDH1A3 with an IC 50 of 1.29 μM. Aldehyde dehydrogenases (ALDHs) are overexpressed in various tumor types including prostate cancer. ALDH1A3-IN-2 has the potential for the research of cancer

ALDH1A3-IN-2 (Compound 15) is a potent inhibitor of ALDH1A3 with an IC 50 of 1.29 μM. Aldehyde dehydrogenases (ALDHs) are overexpressed in various tumor types including prostate cancer. ALDH1A3-IN-2 has the potential for the research of cancer

ALDH1A3-IN-2 (Compound 15) is a potent inhibitor of ALDH1A3 with an IC 50 of 1.29 μM. Aldehyde dehydrogenases (ALDHs) are overexpressed in various tumor types including prostate cancer. ALDH1A3-IN-2 has the potential for the research of cancer

ALDH1A3-IN-2 (Compound 15) is a potent inhibitor of ALDH1A3 with an IC 50 of 1.29 μM. Aldehyde dehydrogenases (ALDHs) are overexpressed in various tumor types including prostate cancer. ALDH1A3-IN-2 has the potential for the research of cancer

ALDH1A3-IN-2 (Compound 15) is a potent inhibitor of ALDH1A3 with an IC 50 of 1.29 μM. Aldehyde dehydrogenases (ALDHs) are overexpressed in various tumor types including prostate cancer. ALDH1A3-IN-2 has the potential for the research of cancer

ALDH3A1-IN-1 (Compound 18) is a potent inhibitor of ALDH3A1 with an IC 50 of 1.61 μM. ALDH3A1-IN-1 is more potent than DEAB against patient-derived primary prostate tumor epithelial cells, as single agents or in combination research with

ALDH3A1-IN-1 (Compound 18) is a potent inhibitor of ALDH3A1 with an IC 50 of 1.61 μM. ALDH3A1-IN-1 is more potent than DEAB against patient-derived primary prostate tumor epithelial cells, as single agents or in combination research with

ALDH3A1-IN-1 (Compound 18) is a potent inhibitor of ALDH3A1 with an IC 50 of 1.61 μM. ALDH3A1-IN-1 is more potent than DEAB against patient-derived primary prostate tumor epithelial cells, as single agents or in combination research with

ALDH3A1-IN-1 (Compound 18) is a potent inhibitor of ALDH3A1 with an IC 50 of 1.61 μM. ALDH3A1-IN-1 is more potent than DEAB against patient-derived primary prostate tumor epithelial cells, as single agents or in combination research with

ALDH3A1-IN-1 (Compound 18) is a potent inhibitor of ALDH3A1 with an IC 50 of 1.61 μM. ALDH3A1-IN-1 is more potent than DEAB against patient-derived primary prostate tumor epithelial cells, as single agents or in combination research with

Aldometanib (LXY-05-029) is an orally active aldolase inhibitor. Aldometanib can activate lysosomal adenosine monophosphate-activated protein kinase (AMPK) and decreases blood glucose. Aldometanib can be used for the research of metabolic

Aldometanib (LXY-05-029) is an orally active aldolase inhibitor. Aldometanib can activate lysosomal adenosine monophosphate-activated protein kinase (AMPK) and decreases blood glucose. Aldometanib can be used for the research of metabolic